Bibliography
- RUBINSTEIN A: Colonic drug delivery. Drug Discov. Today (2005) 2(1):33-37.
- FRIEND DR: New oral delivery systems for the treatment of inflammatory bowel disease. Adv. Drug Deliv. Rev. (2005) 57:247-265.
- KLOTZ U, SCHAWAB M: Topical delivery of therapeutic agents in the treatment of inflammatory bowel disease. Adv. Drug Deliv. Rev. (2005) 57:267-279.
- CHOURASIA MK, JAIN SK: Pharmaceutical approaches to colon targeted drug delivery systems. J. Pharm. Pharmaceut. Sci. (2003) 6:33-66.
- SINHA VR, KUMRIA R: Microbially triggered drug delivery to the colon. Eur. J. Pharm. Sci. (2003) 18:3-18.
- VANDAMME TF, LENOURRY A, CHARRUEAU C, CHAUMEIL JC: The use of polysaccharides to target the colon. Carbohydrate Polym. (2002) 48:219-231.
- SINHA VR, KUMRIA R: Polysaccharides in colon-specific drug delivery. Int. J. Pharm. (2001) 224:19-38.
- SINHA VR, KUMRIA R: Colonic drug delivery: prodrug approach. Pharm. Res. (2001) 18:557-564.
- LEOPOLD CS: Coated dosage forms for colon-specific drug delivery. PSTT (1999) 2:197-204.
- KINGET R, KALALA W, VERVOOT L, VAN DEN MOOTER G: Colonic drug targeting. J. Drug Target. (1998) 6:129-149.
- WATTS PJ, ILLUM L: Colonic drug delivery. Drug Dev. Ind. Pharm. (1997) 23(9):893-913.
- VAN DEN MOOTER G, MARIS B, SAMYN C, AUGUSTIJNS P, KINGET R: Use of azo polymers for colon-specific drug delivery. J. Pharm. Sci. (1997) 86:1321-1327.
- FRIEND DR: Colon-specific drug delivery. Adv. Drug Deliv. Rev. (1991) 7:149-199.
- VAN DEN MOOTER G: Colon drug delivery. Expert Opin. Drug Deliv. (2006) 3(1):111-125.
- IKESUE K, KOPEČKOVA P, KOPEČEK J: Degradation of proteins by guinea pig intestinal enzymes. Int. J. Pharm. (1993) 95:171-179.
- LANGGUTH P, BREVES G, STOCKLI A, MERKLE HP, WOLFFRAM S: Colonic absorption and bioavailability of the pentapeptide metkephamid in the rat. Pharm. Res. (1994) 11:1640-1645.
- FARA JW, MYRBACK RE: Formulation and dosage form design in drug-induced topical irritation of the gastrointestinal tract. Pharm. Res. (1990) 7:616-621.
- RUBINSTEIN A: Approaches and opportunities in colon-specific drug delivery. Crit. Rev. Ther. Drug Carrier Syst. (1995) 12(2&3):101-149.
- WILSON CG, WASHINGTON N: Physiological Pharmaceutics: Biological Barriers to Drug Absorption. (Ed.), Wiley John and sons, Chichester, UK (1989).
- DAVIS SS, HARDY JD, TAYLOR MJ, WHALLEY DR, WILSON CG: A comparative study of the gastrointestinal tansit of a pellet and tablet formulation. Int. J. Pharm. (1984) 21:116-117.
- DAVIS SS, NORRING-CHRISTENSEN F, KHOSLA R, FEELY LC: Gastric emptying of large single unit dosage forms. J. Pharm. Pharmacol. (1988) 40:205-207.
- DEVEREUX JE, NEWTON JM, SHORT MB: The influence of density on the gastrointestinal transit of pellets. J. Pharm. Pharmacol. (1990) 42:500-501.
- PRICE JMC, DAVIS SS, WILDING IR: The effect of fibre on gastrointestinal transit times in vegetarians and omnivores. Int. J. Pharm. (1991) 76:123-141.
- MADSEN JL: Effect of gender, age and body mass index on gastrointestinal transit times. Dig. Dis. Sci. (1992) 37:1548-1553.
- WILDING IR, COUPE AJ, DAVIS SS: The role of α scintigraphy in oral drug delivery. Adv. Drug Deliv. Rev. (1991) 7:87-117.
- DAVIS SS, HARDY JG, FARA JW: Alimentary tract and pancreas: transit of pharmaceutial dosage forms through the small intestine. Gut (1986) 27:886-892.
- DAVIS SS: The design and evaluation of controlled release systems for the gastrointestinal tract. J. Control. Rel. (1985) 2:27-38.
- PHILIPS SF: Transit across the ileocolonic junction. In: Drug Delivery in the Gastrointestinal Tract. Hardy JD et al. (Eds), Ellis Horwood Ltd., Chichester, UK (1989):63-76.
- EVANS DF, PYE G, BRAMLEY R, CLARK AG, DYSON TJ: Measurement of gastrointestinal pH profiles in normal ambulant human subjects. Gut (1988) 29:1035-1041.
- RAIMUNDO AH, EVANS DF, ROGERS J, SILK DBA: Gastrointestinal pH profiles in ulcerative colitis. Gastroenterology (1992) 104:A681.
- HASTEWELL J, WILLIAMSON I, MACKAY M: Cell biology and active transport processes in the colon. Adv. Drug Deliv. Rev. (1991) 7:119-147.
- SICCARDI D, TURNER JR, MRSNY RJ: Regulation of intestinal epithelial function: a link between opportunities for macromolecular drug delivery and inflammatory bowel disease. Adv. Drug Deliv. Rev. (2005) 57:219-235.
- MRSNY R: The colon as a site for drug delivery. J. Control. Rel. (1992) 22:15-34.
- VAN HOOGDALEM EJ, DE BOER AG, BRIEMER D: Intestinal drug absorption enhancement: an overview. Phamacol. Ther. (1989) 44:407-443.
- TOZAKI H, KOMOIKE J, TADA C et al.: Chitosan capsules for colon-specific drug delivery: improvement of insulin absorption from the rat colon. J. Pharm. Sci. (1990) 86(9):1016-1021.
- LEE VHL, YAMAMOTO A: Penetration and enzymatic barriers to peptide and protein absorption. Adv. Drug Deliv. Rev. (1989) 4(2):171-207.
- YAMAMOTO A, HAYAKAWA E, LEE VH: Insulin and proinsulin proteolysis in mucosal homogenates of the albino rabbit: implications in peptide delivery from nonoral routes. Life Sci. (1990) 47(26):2465-2474.
- BAI JPF: Colonic delivery of peptide and protein drugs: consideration of intracellular proteolytic enzymes. STP Pharma Sci. (1995) 5(1):30-35.
- PEETERS M, GEYPENS B, CLAUS D et al.: Clustering of increased small intestinal permeability in families with Crohn's disease. Gastroenterology (1997) 113:802-807.
- TAYLOR CT, DZUS AL, COLGAN SP: Autocrine regulation of epithelial permeability by hypoxia: role of polarized release of TNF-α. Gastroenterology (1998) 114:657-668.
- SAVAGE G: Microbial ecology of the gastrointestinal tract. Annu. Rev. Microbiol. (1997) 31:107-133.
- HILL MJ, DRASAR BS: The normal colonic bacterial flora. Gut (1975) 16:318-323.
- GOLDMAN P: Biochemical pharmacology of the intestinal flora. Annu. Rev. Pharmacol. Toxicol. (1978) 18:523-539.
- KEIGHLEY MRB, ARABI Y, DIMOCK F et al.: Influence of inflammatory bowel disease on intestinal microflora. Gut (1978) 19:1099-1106.
- RUBINSTEIN A: Microbially controlled drug delivery to the colon. Biopharm. Drug Dispos. (1990) 11:465-475.
- SCHELINE RR: Metabolism of foreign compounds by gastrointestinal microorganism. Pharmacol. Rev. (1973) 25:451-523.
- WILDING IR, DAVIS SS, O'HAGAN OT: Targeting drugs and vaccines to the gut. Phamacol. Ther. (1994) 62:97-124.
- LARSEN GL, LARSON JP, GUSTAFSSON JA: Cysteine conjugate β-lyase in the gastrointestinal bacterium Fusobacterium necrophorum. Xenobiotica (1983) 13:687-693.
- MURAOKA M, HU Z, SHIMOKAWA T et al.: Evaluation of intestinal pressure-controlled colon delivery capsule containing caffeine as a model drug in human volunteers. J. Control. Rel. (1998) 52:119-129.
- RADOMSKI JL, MELLINGER TJ: Fate and excretion in rats of soluble azo dyes. J. Pharmacol. Exp. Ther. (1962) 136:259-266.
- GINGELL R, WALKER R: Mechanism of azo reduction by Streptococcus faecalis. II. The role of soluble flavins. Xenobiotica (1971) 1:231-239.
- GRIM Y, KOPEČEK J: Bioadhesive water-soluble polymeric drug carriers for site-specific oral drug delivery. Synthesis, characterization, and release of 5-aminosalicylic acid by Streptococcus faecium in vitro. N. Polym. Mater. (1991) 3(1):49-59.
- BRAGGER JL, LLOYD AW, SOOZANDEHFAR SH et al.: Investigations into the azo reducing activity of a common colonic microorganism. Int. J. Pharm. (1997) 157:61-71.
- MUTAFOV S, AVRAMOVA T, STEFANOVA L, ANGELOVA B: Decolorization of acid orange 7 by bacteria of different tinctorial type: a comparative study. World J. Microbiol. Biotechnol. (2007) 23(3):417-422.
- STOLZ A: Basic and applied aspects in the microbial degradation of azo dyes. Appl. Microbiol. Biotechnol. (2001) 56:69-80.
- ITO K, NAKANISHI M, LEE WC et al.: Three-dimensional structure of AzoR from Escherichia coli – an oxidereductase conserved in microorganisms. J. Biol. Chem. (2006) 281(29):20567-20576.
- DOS SANTOS A, CERVANTES F, VAN LIER J: Review paper on current technologies for decolourisation of textile wastewaters: perspectives for anaerobic biotechnology. Bioresou. Technol. (207) 98:2369-2385.
- BRØNDSTED H, KOPEČEK J: Hydrogels for site-specific dug delivery to the colon: in vitro and in vivo degradation. Pharm. Res. (1992) 9:1540-1545.
- KIMURA Y, MAKITA Y, KUMAGAI T et al.: Degradation of azo-containing polyurethane by the action of intestinal flora: its mechanism and applications as drug delivery system. Polymer (1992) 33:5294-5299.
- YAMAOKA T, MAKITA Y, SASATANI H, KIM SI, KIMURA Y: Linear type azo-containing polyurethane as drug-coating material for colon-specific delivery: its properties, degradation behavior, and utilization for drug formulation. J. Control. Rel. (2000) 66:187-197.
- LLOYD AW, MARTIN GP, SOOZANDEHFAR SH: Azopolymers: a means of colon specific drug delivery? Int. J. Pharm. (1994) 106:255-260.
- NAM S, RENGANATHAN V: Non-enzymatic reduction of azo dyes by NADH. Chemosphere (2000) 40:351-357.
- BROWN MA, DEVITO SC: Predicting azo-dye toxicity. Crit. Rev. Environ. Sci. Technol. (1993) 23(3):249-324.
- KAHN AKA, PIRIS J, TRUELOVE SC: An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet (1977) 2:225-232.
- KAHN AKA, TRUELOVE SC, ARONSEQ JK: The disposition and metabolism of sulphasalazine (salicylazosulphapiridine). Br. J. Clin. Pharmacol. (1982) 13:523-528.
- VAN HOZEGARD RA: Pharmacokinetics of olsalazine and its metabolites. Scand. J. Gastroenterol. (1988) 23S(148):17-20.
- WILLOUGHBY CP, COWAN RE, GOULD SR, MACHELL RJ, STEWART JB: Double-blind comparison of olsalazine and sulphasalazine in active ulcerative colitis. Scand. J. Gastroenterol. (1988) 23(Suppl. 148):40-44.
- BROWN JP, MCGARRAUGH GV, PARKINSON TM, WINGARD RE, ONDERDONK AB: A polymeric drug for the treatment of inflammatory bowel disease. J. Med. Chem. (1983) 26:1300-1307.
- MCVEY DC, LIDDLE RA, RIGGS-SAUTHIER J, EKWURIBE N, VIGNA SR: Inhibition of Clostridium difficile toxin A-induced colitis in rats by APAZA. Dig. Dis. Sci. (2005) 50(3):565-573.
- WIWATTANAPATAPEE R, LOMLIM L, SARAMUNEE K: Dendrimers conjugates for colonic delivery of 5-aminosalicylic acid. J. Control. Rel. (2003) 88:1-9.
- SCHACHT E, GEVAERT A, REFAIE KENAWY E et al.: Polymers for colon specific drug delivery. J. Control. Rel. (1996) 39:327-338.
- MOLLY K, VANDE WOESTYNE M, VERSTRAETE W: Development of a 5-step multi-chamber reactor as a simulation of the human intestinal microbial ecosystem. Appl. Microbiol. Biotechnol. (1993) 39:254-258.
- MAHKAM M, ASSADI MG, ZAHEDIFAR R, RAMESH M, DAVARAN S: Linear type azo-containing polyurethanes for colon-specific drug delivery. J. Bioact. Compat. Polym. (2004) 19:45-53.
- LAI J, WANG LQ KT, ZHAO C, SUN W: Linear azo polymer containing conjugated 5,5′-azodisalicylic acid segments in the main chain: synthesis, characterization, and degration. Macromol. Rapid Commun. (2005) 26:1572-1577.
- MAHKAM M, ASSADI MG, ZAHEDIFAR R et al.: Synthesis and evaluation of a new linear azo-polymer for colonic targeting. Des. Monomers Polym. (2004) 7(4):351-359.
- DAVARAN S, RASHIDI MR, HANAEE J, KHANI A, HASHEMI M: Synthesis and degradation characteristics of polyurethanes containing azo derivatives of 5-amino salicylic acid. J. Bioact. Compat. Polym. (2006) 21:315-326.
- KLOTZ U: Colonic targeting of aminosalicylates for the treatment of ulcerative colitis. Dig. Liver Dis. (2005) 37(6):381-388.
- KOPEČKOVA P, KOPEČEK J: Release of 5-aminosalicylic acid from bioadhesive N-(2-hydroxypropyl)methacrylamide copolymers by azoreductases in vitro. Makromol. Chem. (1990) 191:2037-2045.
- SAKUMA S, LU ZR, KOPEČKOVA P, KOPEČEK J: Biorecognizable HPMA copolymer-drug conjugates for colon-specific delivery of 9-aminocaptothecin. J. Control. Rel. (2001) 75:365-379.
- LU ZR, GAO SQ, KOPEČKOVA P, KOPEČEK J: Synthesis of bioadhesive lectin-HPMA copolymer-cyclosporin conjugates. Bioconjug. Chem. (2000) 11:3-7.
- IZHAR M, NUCHAMOWITZ Y, MIRELMAN D: Adherence of Shigella flexneri to guinea pig intestinal cells is mediated by a mucosal adhesion. Infect. Immun. (1982) 35:1110-1118.
- MIRELMAN D, IZHAR M, ESHDAT-TOKAI J: Carbohydrate recognition mechanisms which mediate microbial adherence to mammalian mucosal surfaces. J. Exp. Clin. Med. (1982) 7(Suppl.):177-183.
- SAKUMA S, LU ZR, PECHAROVA B, KOPEČKOVA P, KOPEČEK J: N-(2-hydroxypropyl)methacrylamide copolymer-9-aminocamptothecin conjugate: colon-specific delivery in rats. J. Bioact. Compat. Polym. (2002) 17:305-319.
- TOKI BE, CERVENY CG, WAHL AF, SENTER PD: Protease-mediated fragmentation of p-amidobenzyl ethers: a new strategy for the activation of anticancer prodrugs. J. Org. Chem. (2002) 67(2002):1866-1872.
- DE GROOT FM, LOOS WJ, KOEKKOEK R et al.: Elongated multiple electronic cascade and cyclization spacer system in activatible anticancer prodrugs for enhanced drug release. J. Org. Chem. (2001) 66:8815-8830.
- GAO SQ, LU ZR, PETRI B, KOPEČKOVA P, KOPEČEK J: Colon-specific 9-aminocamptothecin-HPMA copolymer conjugates containing a 1,6-elimination spacer. J. Control. Rel. (2006) 110:323-331.
- GAO SQ, LU ZR, KOPEČKOVA P, KOPEČEK J: Biodistribution and pharmacokinetics of colon-specific HPMA copolymer-9-aminocamptothecin conjugate in mice. J. Control. Rel. (2007) 117:179-185.
- KAKOULIDES E, SMART JD, TSIBOUKLIS J: Azocrosslinked poly(acrylic acid) for colonic delivery and adhesion specificity: synthesis and characterisation. J. Control. Rel. (1998) 52(3):291-300.
- KAKOULIDES EP, SMART JD, TSIBOUKLIS J: Azocrosslinked poly(acrylic acid) for colonic delivery and adhesion specificity: in vitro degradation and preliminary ex vivo bioadhesion studies. J. Control. Rel. (1998) 54(1):95-109.
- ROLDO M, BARBU E, BROWN J et al.: Orally administered, colon-specific mucoadhesive azopolymer particles for the treatment of inflammatory bowel disease: an in vivo study. J. Biomed. Mater. Res. A (2006) 79A(3):706-715.
- APPLEYARD CB, WALLACE JL: Reactivation of hapten-induced colitis and its prevention by anti-inflammatory drugs. Am. J. Physiol. Gastrointest. Liver Physiol. (1995) 269:G119-G125.
- SAKKINEN M, MARVOLA J, KANERVA H et al.: Are chitosan formulations mucoadhesive in the human small intestine? An evaluation based on γ scintigraphy. Int. J. Pharm. (2006) 307:285-291.
- PATEL M, SMART J, NEVELL T et al.: Mucin/poly(carboxylic acid) interactions: a spectroscopic investigation of mucoadhesion. Biomacromolecules (2003) 4(5):1184-1190.
- HOFFMAN AS: Hydrogels for biomedical applications. Adv. Drug Deliv. Rev. (2002) 54:3-12.
- GUPTA P, VERMANI K, GARG S: Hydrogels: from controlled release to pH-responsive drug delivery. Drug Discov. Today (2002) 7(10):569-579.
- HAMIDREZA G, KOPEČKOVA P, YEH PY, KOPEČEK J: Biodegradable and pH-sensitive hydrogels: synthesis by a polymer–polymer reaction. Macromol. Chem. Phys. (1996) 197:965-980.
- BRØNDSTED H, KOPEČEK J: Hydrogels for site-specific oral drug delivery: synthesis and characterization. Biomaterials (1991) 12:584-592.
- YEH PY, BERENSON MM, SAMOWITZ WS, KOPEČKOVA P, KOPEČEK J: Site-specific drug delivery and penetration enhancement in the gastrointestinal tract. J. Control. Rel. (1995) 36:109-124.
- GHANDEHARI H, KOPEČKOVA P, KOPEČEK J: In vitro degradation of pH-sensitive hydrogels containing aromatic azo bonds. Biomaterials (1997) 18:861-872.
- SHANTHA KL, RAVICHANDRAN P, PANDURAGA RAO K: Azo polymeric hydrogels for colon targeted drug delivery. Biomaterials (1995) 16:1313-1318.
- STUBBE B, MARIS B, VAN DEN MOOTER G, DE SMEDT SC: The in vitro evaluation of “azo containing polysaccharide gels” for colon delivery. J. Control. Rel. (2001) 75:103-114.
- VERVOOT L, VAN DEN MOOTER G, AUGUSTIJNS P et al.: Inulin hydrogels as carriers for colonic drug targeting. I. Synthesis and characterisation of methacrylated inulin and hydrogel formation. Pharm. Res. (1997) 12:1730-1737.
- MARIS B, VERHEYDEN L, VAN REETH K et al.: Synthesis and characterisation of inulin-azo hydrogels designed for colon targeting. Int. J. Pharm. (2001) 213:143-152.
- LIU ZL, HU H, ZHUO RX: Konjac glucomannan-graft-acrylic acid hydrogels containing azo crosslinker for colon-specific delivery. J. Polym. Sci. [A1] (2004) 42(17):4370-4378.
- YIN Y, YANG YJ, XU H: Hydrophobically modified hydrogels containing azoaromatic coss-links: swelling properties, degradation in vivo and application in drug delivery. Eur. Polym. J. (2002) 38:2305-2311.
- SAFFRAN M, KUMAR GS, SAVARUAR C et al.: A new approach to the oral administration of insulin and other peptide drug. Science (1986) 233:1081-1084.
- TOZAKI H, NISHIOKA J, KOMOIKE J et al.: Enhanced absorption of insulin and (Asu1,7)Eel-calcitonin using novel azopolymer-coated pellets for colon-specific drug delivery. J. Pharm. Sci. (2001) 90:89-97.
- VAN DEN MOOTER G, SAMYN C, KINGET R: Azo polymers for colon-specific drug delivery. Int. J. Pharm. (1992) 87:37-46.
- VAN DEN MOOTER G, SAMYN C, KINGET R: Characterization of colon-specific azo polymers: a study of the swelling properties and the permeability of isolated polymer films. Int. J. Pharm. (1994) 111:127-136.
- VAN DEN MOOTER G, SAMYN C, KINGET R: The relation between swelling properties and enzymatic degradation of azo polymers designed for colon-specific drug delivery. Pharm. Res. (1994) 11:1737-1741.
- JAIN SK, CHOURASIA MK, DENGRE R: Azo polymers for colon targeted drug delivery. Indian J. Pharm. Sci. (2005) 67(1):43-50.
- LOW PS: Folate receptor-targeted imaging and therapeutic agents for cancer and inflammation. (Ed.), Proceedings of International Symposium on Polymer Therapeutics, Berlin (DE) (2007).
- PAULOS CM, TURK MJ, BREUR GJ, LOW PS: Folate receptor-mediated targeting of therapeutic and imaging agents to activated macrophages in rheumatoid arthritis. Adv. Drug Deliv. Rev. (2004) 56(8):1205-1217.
Patents
- MACNEIL ME, RASHID A, STEVENS HNE: WO9009168 (1990).
- EKWURIBE NN, ODENBAUGH AL: US20060167234A1 (2006).